-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Several Flagship Products from Shijiazhuang Sihua Pharmaceutical Group Energize the National Pharmaceutical Fair
Category:
发布时间：2024-11-21
【概要描述】
In early winter, the land of Jingchu is washed clean by rain, with shimmering lake waters and lush, layered greenery, creating a vibrant and colorful tapestry everywhere. On November 20, the highly anticipated 89th National Pharmaceutical Trade Fair grandly opened at the Wuhan International Expo Center along the banks of the Yangtze River. Shijiazhuang Sihua Pharmaceutical Group, one of China’s top 100 pharmaceutical companies, showcased a range of blockbuster products, promoting its brand and new offerings while sharing new opportunities for development with pharmaceutical purchasers, distributors, and industry peers.
In early winter, the land of Jingchu is bathed in gentle rain that sweeps away the dust, revealing shimmering lake waters and lush, layered greenery—every corner alive with vibrant colors. On November 20, the highly anticipated 89th National Pharmaceutical Trade Fair grandly opened at the Wuhan International Expo Center along the banks of the Yangtze River. Shijiazhuang No.4 Pharmaceutical Group, one of China’s top 100 pharmaceutical companies, showcased a range of blockbuster products, highlighting its brand and introducing new offerings, while sharing new opportunities for growth with pharmaceutical buyers, distributors, and industry peers.
The National Pharmaceutical Trade Fair, organized by Sinopharm Expo, is a large-scale and highly influential event in China’s pharmaceutical preparations and greater health sectors. This year’s exhibition features products spanning chemical drugs, proprietary Chinese medicines, traditional Chinese medicinal herbs, formulated granules, OTC medications, medical consumables, medical devices, pharmaceutical R&D supply chains, pharmaceutical logistics technologies and equipment, Internet-plus healthcare, and smart marketing—covering a wide range of specialized industry clusters. The event hosts more than 2,000 domestic and international exhibitors and attracts over 100,000 professional visitors from across China and overseas.
At the exhibition, the Group’s custom-designed booth was grand, minimalist, and spacious, with a prominent display of numerous blockbuster products, including sitagliptin dry-mix suspension, pentoxifylline sustained-release tablets, peritoneal dialysis solution, fat emulsion (10%)/amino acids (15%)/glucose (20%) injection, and etomidate medium- to long-chain fat emulsion injection. “Shisi Pharmaceutical has launched a remarkable number of new products over the past two years—truly impressive growth momentum!” Business clients and industry professionals visiting the Group’s booth were overwhelmed by the sheer variety and quality of its offerings, expressing deep admiration for the company’s development. They eagerly stopped by to engage in discussions and negotiations with the Group’s sales representatives, creating a bustling crowd and an exceptionally vibrant atmosphere.
“This is our independently developed aseptic stand-up pouch, featuring an advanced dual-layer aseptic design that effectively maintains the sterility of pharmaceutical products throughout storage and transportation. This not only enhances drug safety but also simplifies clinical use and handling for healthcare professionals,” explained a specialist from the Group’s Marketing Center to visiting customers at the exhibition.
On the LED display screen at one side of the booth, the group’s newly launched flagship products—such as rasagiline mesylate tablets and carbidopa–levodopa extended-release tablets—stood out prominently, drawing a large crowd of business visitors. Journalists from media outlets including Jingchu Net and Hebei Economic Daily also flocked to the group’s booth to set up their equipment and conduct on-site interviews.
In recent years, the Group has thoroughly implemented the new development philosophy, taking it as its mission to research, develop, and manufacture more “Chinese medicines” that are tailored to the genetic heritage and physical characteristics of the Chinese population. With high-quality development as its top priority, the Group has focused on the cutting edge of industry development, rigorously pursued an innovation-driven strategy, and relentlessly advanced the integrated development of the innovation chain, talent chain, industrial chain, and supply chain. It has continuously fostered and expanded new productive forces, concentrating on key therapeutic areas such as anti-infection, respiratory, neurological, cardiovascular and cerebrovascular, digestive, anesthesia, endocrine, oncology, and dialysis, while actively building a high-energy ecosystem for high-quality development. Product innovation has been strategically orchestrated to form a cohesive value chain and cluster effects. Through iterative product innovation, the Group has accumulated substantial achievements that have now begun to yield significant results, leading to an increasingly diversified and optimized product portfolio. Currently, the product pipeline covers 13 major therapeutic classes and 9 therapeutic areas, comprising 228 dosage forms across 341 specifications, including 155 items covered by basic medical insurance and 56 essential medicines. A total of 107 products in 140 specifications have received approval through consistency evaluation. Since 2023, the Group has maintained strong momentum in innovation, with the number of newly submitted and approved products ranking among the highest in the industry. As a result, its innovative influence and market competitiveness have undergone a remarkable transformation and leap forward, earning widespread recognition within the industry.
“Is it not a joy to have friends come from afar?” On the first day of the exhibition, as night fell and the city lights began to twinkle, the “River City” unveiled a unique charm. A grand appreciation banquet was held at the Wuhan Fuli Wanda Jia Hua Hotel on the shores of East Lake, bringing together more than 400 dealers and agents from across the country, along with Group Chairman Su Xuejun, to discuss a new vision and future for collaborative development between industry and commerce. The banquet was hosted by Qu Benyue, Executive President of the Group.
At the appreciation ceremony, Zhen Zhanjun, Group Executive President and General Manager of the Pharmaceutical Business Unit, delivered a welcoming address, extending sincere greetings to both new and existing customers and expressing heartfelt gratitude for their trust, support, and patronage of Shijiazhuang Sihua Pharmaceutical.
Amid warm applause, Chairman Su Xuejun delivered a speech of thanks. He noted that Shijiazhuang No. 4 Pharmaceutical has weathered 76 years of trials and tribulations, and in this new era and on this new journey, it is embracing innovation and striving for excellence. An increasing number of innovative achievements are being translated into the company’s market strength, competitive edge, and developmental advantages, enabling it to advance with ever greater resolve and momentum. The dynamism unleashed by this development provides broader space and more abundant opportunities for expanding mutual cooperation. He stated that, in the face of today’s severe and complex market conditions—where opportunities and challenges coexist—he sincerely hopes that all partners will continue to consolidate and deepen the foundations and bonds of win-win cooperation, offering each other support, working together in tandem, and jointly overcoming difficulties, so as to write a new chapter of shared development and mutual benefit and make new and even greater contributions to building a Healthy China.
At the appreciation reception, the Marketing Center of the Group’s Pharmaceutical Business Unit provided guests with a comprehensive overview of the company’s product pipeline and marketing management standards. Outside the reception venue, meticulously arranged exhibition booths showcased the company’s new products, with targeted emphasis on their distinctive features and market advantages.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091